Media ReleasesImugene Limited

View All Imugene Limited News

Imugene PD1-Vaxx Immunotherapy Update

Sydney, Australia, 28 January 2020: Imugene Limited (ASX:IMU) a clinical stage immuno-oncology company today announces a clinical development update on its PD1-Vaxx cancer immunotherapy. PD1- Vaxx will be trialled in patients with non-small cell lung cancer (NSCLC), the most common type of lung cancer, accounting for around 80% of cases. The study is planned to commence in 2020 and is to be conducted at up to 6 sites in North America and Australia under a U.S. Food & Drug Administration (FDA) Investigational New Drug (IND) application.

• GMP manufacturing including sterile fill and finish complete
• All preclinical toxicology studies complete allowing confirmation of clinical dose levels
• Toxicology studies confirm PD1-Vaxx generates high levels of antibodies

For further information, please download the attached PDF

Download this document

Subscribe to our Daily Newsletter?

Would you like to receive our daily news to your inbox?